This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| BWS | |
|---|---|
| Name | BWS |
| Field | Pediatrics, Medical genetics, Neonatology |
| Onset | Congenital disorder |
| Prognosis | Variable |
BWS
Beckwith–Wiedemann spectrum (BWS) is a congenital overgrowth and tumor predisposition condition first described in clinical series by John B. Beckwith and Hans-Rudolf Wiedemann. It presents with heterogeneous features including macrosomia, macroglossia, organomegaly, and predisposition to embryonal tumors such as Wilms tumor and Hepatoblastoma. Management typically involves multidisciplinary teams drawn from Pediatrics, Pediatric oncology, Medical genetics, and Surgery with surveillance protocols influenced by molecular subtypes and tumor risk.
Terminology for the condition has evolved: classical eponyms and spectrum descriptors appear alongside molecular subclassifications such as 11p15 imprinting center defects, suggesting links to genomic imprinting and specific epigenetic designations. Commonly used abbreviations include IC1 and IC2 for imprinting control regions, LOI for loss of imprinting, UPD for uniparental disomy (often specified as paternal UPD), and MLID for multilocus imprinting disturbance. Clinical shorthand also references tumor surveillance algorithms such as AFP monitoring for Hepatoblastoma and abdominal ultrasound for Wilms tumor.
Phenotypic manifestations span neonates, infants, and children. Frequent features include macrosomia with accelerated growth at birth, macroglossia producing feeding and airway issues requiring evaluation by Otolaryngology and Cleft palate teams, and anterior abdominal wall defects such as omphalocele prompting involvement of Pediatric surgery. Organomegaly can include hepatomegaly and nephromegaly detected by Ultrasonography and cross-sectional imaging. Hemihyperplasia (asymmetric overgrowth) links to limb-length discrepancy and orthopedic concerns addressed by Orthopedics. Ear creases, neonatal hypoglycemia managed in Neonatal intensive care unit, and facial nevus flammeus are among reported signs. Tumor predisposition most notably involves Wilms tumor, Hepatoblastoma, Neuroblastoma, and other embryonal neoplasms requiring coordination with Pediatric oncology.
BWS is primarily a disorder of the 11p15.5 chromosomal region consisting of two imprinting control regions (IC1 and IC2) that regulate expression of growth-regulatory genes such as IGF2 and CDKN1C. Molecular mechanisms include loss of methylation at IC2, gain of methylation at IC1, paternal uniparental disomy of 11p15, and point mutations in CDKN1C. Multilocus imprinting disturbance (MLID) implicates broader defects in imprinting machinery linked to genes involved in DNA methylation maintenance; associations have been investigated with proteins and complexes referenced in studies of DNMT1, DNMT3A, and ZFP57. Assisted reproductive technologies such as In vitro fertilization have been reported at increased frequency among some molecular subgroups, raising etiologic hypotheses examined alongside familial CDKN1C mutations described in pedigree studies.
Diagnosis integrates clinical scoring systems with molecular testing. Clinical diagnostic criteria derive from cardinal and suggestive findings and are used to prioritize molecular assays. Molecular confirmation employs methylation-sensitive techniques, allele-specific assays for uniparental disomy, and sequencing of CDKN1C. Differential diagnosis includes overgrowth syndromes and tumor predisposition disorders such as Sotos syndrome, Russell–Silver syndrome, Proteus syndrome, and Pallister–Hall syndrome, requiring targeted evaluations by Clinical genetics and subspecialists. Prenatal detection can occur via ultrasound identification of omphalocele or macrosomia and through targeted molecular testing of chorionic villus sampling or amniocentesis when family history or assisted reproduction raises suspicion.
Management is multidisciplinary and individualized to phenotype and molecular subtype. Neonatal care addresses hypoglycemia with glucose monitoring and metabolic management under Endocrinology guidance. Airway and feeding problems from macroglossia may require interventions by Otolaryngology and Craniofacial surgery, including tongue reduction when indicated. Abdominal wall defects prompt surgical repair by Pediatric surgery. Tumor surveillance protocols stratified by molecular risk recommend periodic abdominal ultrasonography and serum alpha-fetoprotein (AFP) monitoring, coordinated with Pediatric oncology and national surveillance guidelines. Long-term follow-up addresses growth, developmental, dental, and orthopedic sequelae through allied specialties such as Speech-language pathology, Dentistry, and Physical therapy.
Prognosis varies with phenotype, molecular etiology, and timeliness of tumor surveillance. Early detection of tumors generally yields favorable oncologic outcomes with standard pediatric cancer therapies and surgery. Morbidity can arise from airway compromise, recurrent hypoglycemia, and surgical complications; neurodevelopmental outcomes depend on neonatal metabolic control and associated anomalies. Epidemiologic estimates indicate an incidence in the range reported by population series and referral registries, with some studies noting increased prevalence among children conceived by assisted reproductive technologies. Familial recurrence risk is elevated with inherited CDKN1C mutations but low for most epigenetic causes; genetic counseling in Clinical genetics remains central.
Active research areas include genotype–phenotype correlations across IC1, IC2, and UPD subgroups, mechanisms of MLID, and the impact of assisted reproduction on imprinting errors. Controversies persist regarding optimal surveillance intervals, AFP threshold cutoffs, and indications for early surgical interventions such as prophylactic tongue reduction. Experimental approaches explore epigenetic editing and targeted modulation of imprinting marks, informed by basic research on imprint maintenance factors and clinical trials in pediatric oncology networks. Collaborative registries and longitudinal cohorts, including multicenter initiatives in Europe and North America, aim to refine risk stratification and long-term outcome data.
Category:Genetic disorders